Track RAPT Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

RAPT Therapeutics, Inc. RAPT · Stock Open RAPT Therapeutics, Inc. in new tab

58.01 USD
EPS
-11.66
P/B
6.43
ROE
-85.37
Beta
0.44
Loading chart...
Key Metrics
Earnings dateMay 6, 2026
EPS-11.66
Book Value9.02
Price to Book6.43
Debt/Equity1.71
% Insiders0.276%
Estimates
Forward P/E-21.38
Forward EPS-2.71

DCF valuation

Model fair value for RAPT Therapeutics, Inc. (RAPT)
Result
Sign in to run the valuation for RAPT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

RAPT Therapeutics, Inc. Logo RAPT Therapeutics, Inc. Analysis (RAPT)

United States Health Care Official Website Stock

Is RAPT Therapeutics, Inc. a good investment? RAPT Therapeutics, Inc. (RAPT) is currently trading at 58.01 USD.

Earnings Schedule: RAPT Therapeutics, Inc. is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is -2.71.

Investor FAQ

Does RAPT Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is RAPT Therapeutics, Inc.?

RAPT Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of -11.66.

Company Profile

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.

Exchange Ticker
MUN (Germany) 0RA.MU
NMS (United States) RAPT
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 17, 2025 0.12
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion